Imaging biomarkers in prostate cancer: role of PET/CT and MRI

Picchio, Maria; Mapelli, Paola; Panebianco, Valeria; Castellucci, Paolo; Incerti, Elena; Briganti, Alberto; Gandaglia, Giorgio; Kirienko, Margarita; Barchetti, Flavio; Nanni, Cristina; Montorsi, Francesco; Gianolli, Luigi; Fanti, Stefano

doi:10.1007/s00259-014-2982-5

Cited by 56 publications

(38 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several PET tracers are in routine clinical use for PC staging, including 18 F-choline and 11 C-acetate, both of which are superior to the standard oncological tracer 18 F-deoxyglucose [13]. Nevertheless, the moderate sensitivity and specificity of these tracers are not sufficient to accurately stage the primary tumour [14].…”

Section: Discussionmentioning

confidence: 99%

Molecular imaging of cholinergic processes in prostate cancer using 11C-donepezil and 18F-FEOBV

Stokholm

Høyer

Borre

et al. 2015

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular imaging of cholinergic processes in prostate cancer using 11C-donepezil and 18F-FEOBV

Stokholm

Høyer

Borre

et al. 2015

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…In oncology, PET/MRI might show improvements in regions and tumors where MR is known to be superior to CT (i.e., soft tissue sarcomas, head and neck cancer, and pelvic tumors), while maintaining the degree of functional information provided by PET. Prostate cancer patients will particularly benefit from PET/MRI thanks to the combined simultaneous acquisition of multiparametric MR and PETtargeted radiopharmaceuticals such as choline-labeled ligands and those that target specific tumor molecules, such as the prostate-specific membrane antigen [3].…”

mentioning

confidence: 99%

Current status and future perspectives of PET/MRI hybrid imaging

Picchio

Pampaloni

2016

Clin Transl Imaging

View full text Add to dashboard Cite

The success of hybrid PET/CT imaging over the last decade was mainly based on the complementary information it provided. The integration of a primarily morphologic technique such as CT with a functional modality like PET enabled the better and more accurate characterization and localization of in vivo processes. It appears therefore natural to believe that the recent development of combined PET/MRI devices would represent the next step in hybrid imaging by capturing the unique characteristics offered by MRI. By combining the exquisite anatomical and functional information offered by MRI with metabolic data from PET imaging, a new era of exciting new research and clinical possibilities seems to be unfolding.While the full scope of PET/MRI applications remains to be defined, the recent initial experience has shown advances in protocol design, image reconstruction, data processing, and image interpretation. Despite these promising results suggest that the medical community could now focus in an optimization and standardization of the patient workflow for developing new clinical indications, incomplete resolution of attenuation correction protocols and the search for the incremental value of PET/MRI when compared to the current standard of care PET/CT still need to be entirely sort out.This concurrent imaging protocol facilitates the MR acquisition of not only morphological information but also pathophysiological data. When combined with the biochemical, metabolic, and kinetic biodistribution changes provided by PET, this synergy of added functional information could surpass what PET/CT has currently to offer. Multiple efforts are underway to gather the required prospective instrumentation and clinical data to delineate the most cost-effective applications of this new technology. The available data show that PET/MRI is clinically feasible and performs as well as PET/CT in most types of cancer. However, in the majority of PET/MRI clinical researches, MRI images were used to provide anatomic details for PET signal, rather than focusing on the potential synergy between the capabilities of functional MRI and molecular PET [1].In addition, given the potential for technological development, efforts should also be made by researchers to compare the diagnostic performance of the two hybrid imaging technologies and their influence on further clinical management, in particular by fully exploring the potential of PET/MRI.Although there is still a lack of clearly defined PET/MRI key applications, there are some obvious advantages on using PET/MRI over PET/CT that cannot be unnoticed: there are all the clinical cases where patients need to perform both PET and MRI studies for the evaluation of their disease. The opportunity of performing both examinations in the same study session is a clear benefit in term of patient convenience, being easier than having to go for a PET and MR separately, and much less time-consuming. Another great advantage of PET/MR with respect to PET/ CT is that patients have much less radiation exposure: M...

show abstract

“…In particular, PET/CT and multiparametric MRI (mp-MRI) have provided substantial and crucial advances in the detection and localization of both local and distant PCa recurrence [4].…”

mentioning

confidence: 99%